Trending...
- Allegiant Management Group Launches New Website Following Recent Rebranding
- And The Winner Is: Special Request Ft Rey T (AKA) Reynard Thomas
- The Ultimate Guide to Buying Historic Luxury Homes in Winter Park, FL Now Available
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Virginir -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on virginir.com
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on virginir.com
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on virginir.com
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- Benchmark International Faciltd the Trans BT Boost Strategy Partners, LLC & ImageTech Systems
- ASA to Host New Webinar on Techniques and Challenges of Fei Cui (More than Jadeite) Identification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on virginir.com
- ASA Announces 2024 Award Winners
- Sidow Sobrino's My Amir in the Running for GRAMMY® Nominations
- OneGlobe wins seat on DLA JETS 2.0 Multi-Award IDIQ
- Reliance Aerotech Inc. Announces Appointment Of Ron Jordan To Chief Strategy Officer
- Stop Fighting, Start Living. Daryl Dittmer's New Book Offers Roadmap to Personal Power
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on virginir.com
- Celebrating 30 Years: 2024 Diversity Visa Lottery Opens Oct. 2, Offering Life-Changing Opportunities for U.S. Immigration
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
- Wagoner Roofing Launches New Website
- L-Strategies LLC terminates Angie Wong Miami Republican Committeewoman's contract with New Federal State of China NFSC
- Sara Abbas Excites Global Listeners With Much-Anticipated Viral Release Of New Single "Love You From A Distance"
- Horion M6APro Series IFPs Achieves Google EDLA Certification
- How to Get a Handicap Placard in California: Simplifying the Process for Disabled Drivers HandicapMD.com Offers Easy Online Certification for Disabled
- Use Bitcoin to Earn Bitcoin - Innovative Layer 2 Solution for Bitcoin
- Dr Joy Dental Clinic Recognized as a Superbrand for 2024
- T&S Communications at the 25th China International Optoelectronic Exposition (CIOE)
- Master Financial Reporting Valuations: Insights from ME215 for Machinery & Equipment Appraisers
- InventHelp Inventor Develops Solar Charging Feature for Electric Cars (RKH-633)
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New Doctor of Behavioral Health Graduates
- G2 Names iMIS® a Leader in Association Management and Non-Profit CRM Software for the 7th Year in a Row
- Local Provider Roadrunner Health Services Outperforms Corporate Competitors in New Mexico's Correctional Facilities
- FORT Announces Grand Opening of Second Location in Richmond, VA
- Non Profit Organization "The Breast Cancer Fundraiser" Prepares for Breast Cancer Awareness Month
- Leading Arizona Real Estate Team Rebrands to SPACE, Marking a New Era in Real Estate Innovation
- JOHN MOBERLY JOINS IBEOS AS CHIEF GROWTH OFFICER AND GM OF GOVERNMENT PROGRAMS
- Office Calgary Inc has Partnered with RingCentral to provide Telecommunications Systems